Blauvelt, A. ., H. . Sofen, J. . Lambert, J. F. . Merola, M. . Lebwohl, K. . Hoyt, S. Banerjee, T. . Scharnitz, and J. J. . Crowley. “Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 4, July 2024, p. s405, doi:10.25251/skin.8.supp.405.